ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This study provides evidence that individual TP53 hotspot mutations have different impact on HGSOC patient outcomes and potentially TP53 function.
|
31780779 |
2020 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Targeting HDAC4, HIF-1α and CREBZF may be considered in treatment of ovarian cancer with p53 and RAS mutations.
|
30867818 |
2019 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Using cell lines representative of P53 wild-type ovarian cancer (A2780), and P53 mutant ovarian cancer (SKOV3), cells were implanted in the flank of athymic nude female mice.
|
31827119 |
2019 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
We performed genome-wide copy number aberration (CNA) profiles and mutation hotspot screening (KRAS, BRAF, NRAS, ERBB2, PIK3CA, TP53) in 38 LGSOC tumor samples.
|
31054497 |
2019 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Resistance to chemotherapy and high heterogeneity in mutations contribute to ovarian cancer's lethality, including many mutations in tumor suppressor p53.
|
31039796 |
2019 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Collectively, the present study suggested that CALB1 may act as an oncogene in ovarian cancer by inhibiting the p53 pathway.
|
31059057 |
2019 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Improvements in mutational profiling have provided valuable insight, such as the ubiquity of TP53 mutations in HGSOC tumors.
|
31187121 |
2019 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
High expression of the three transketolase genes was associated with unfavorable PFS in patients with TP53-mutated ovarian cancer, but not in patients with TP53 wild-type ovarian cancer.
|
31611995 |
2019 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
TP53 pathway may play pivotal roles in the development of ovarian cancer and TP53 pathway may be a new target for the treatment of ovarian cancer.
|
29565482 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
CTD_human |
Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers.
|
30258081 |
2018 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Because chemokine network is involved in OC progression, we evaluated associations between chemokine expression and survival in tumor suppressor protein p53 (<i>TP53</i>) wild-type (<i>TP53</i>WT) and mutant (<i>TP53</i>m) OC datasets.
|
30181917 |
2018 |
ovarian neoplasm
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
The association between p53 protein phosphorylation at serine 15, serine 20 and sensitivity of cells isolated from patients with ovarian cancer and cell lines to chemotherapy in in vitro study.
|
29684847 |
2018 |
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the association between lifestyle and reproductive factors and risk of ovarian cancer defined by p53 and MAPK expression.<b>Methods:</b> Epithelial ovarian cancer cases (<i>n</i> = 274) and controls (<i>n</i> = 1,907) were identified from the Nurses' Health Study and Nurses' Health Study II prospective cohorts, and the population-based New England Case-Control study.
|
29133366 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
With lead times ≤6 months, ovarian cancer detection sensitivity at 0.98 specificity (SE98) varied from 0.19 [95% CI 0.08-0.40] for CTAG1A, CTAG2 and NUDT1 to 0.23 [0.10-0.44] for P53 (0.33 [0.11-0.68] for high-grade serous tumors).
|
29473162 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Positive protein expressions of AIB1, Bcl-2, and p53 were identified in the epithelial ovarian cancer tissues, and with an increase in the tumor staging of ovarian cancer, we found that the positive protein expression rate was gradually augmented.
|
30178833 |
2018 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The results of direct sequence analysis revealed that the ovarian cancer contains a 1 bp deletion in exon 8 of TP53.
|
29703236 |
2018 |
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The icaritin-induced OC cell apoptosis may be associated with the activation of p53 and the suppression of Akt/mTOR pathway.
|
29625193 |
2018 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We analyzed mRNA expression of <i>PD-1</i>, <i>PD-L1</i> and <i>IFNG</i> by quantitative real-time PCR in tissue of 170 patients with low grade-serous (LGSOC), high-grade serous (HGSOC), endometrioid and clear cell OC compared to 28 non-diseased tissues (ovaries and fallopian tubes) in relation to tumor protein 53 (<i>TP53</i>) and breast cancer gene 1/2 (<i>BRCA1/2</i>) mutation status.
|
29707124 |
2018 |
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Role of Survivin and p53 Expression in Response of Primary Culture of Ovarian Cancer Cells to Treatment With Chemotherapeutic Agents.
|
29727353 |
2018 |
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Knowing that p53 expression status is used for chemotherapeutic approaches and prognosis in ovarian cancer, the results obtained highlight the importance of locating TP53 mutations.
|
29422776 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
We demonstrate that deleterious TP53 variants identified in blood-derived DNA of 523 patients with ovarian cancer (AGO-TR1 trial) were not causal for the patients' ovarian cancer in three out of six TP53-positive cases.
|
30216591 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
In the present study we extended these studies to identify the molecular pathways regulated by QC to promote apoptosis independent of p53 status in OC.
|
29410485 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that Ssd could sensitize OVCA to CDDP independent of the p53 status through multiple signaling pathways.
|
29245943 |
2017 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
We screened ovarian tumor (OTU) subfamily proteins to identify novel DUBs that stabilized p53.
|
28216291 |
2017 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
TP53 Mutations in Breast and Ovarian Cancer.
|
27815305 |
2017 |